Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$130.91 ▼ -0.27
(-0.21%)
MKT CAP: $14.89B • VOL: 1.40M
52W L $61 52W H $134
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$110
MEDIAN
$147
MEAN
$149
HIGH
$178
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE HALO TAPE
HALO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $158.40 | $150.55 | 2025-02-14 | $119.13 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $164.95 | $154.47 | 2025-02-06 | $123.06 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $149.24 | $144.00 | 2025-01-29 | $125.67 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $133.53 | — | 2025-01-17 | $128.29 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $115.20 | $124.36 | 2025-01-09 | $116.51 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $155.78 | $136.15 | 2024-12-18 | $113.89 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $126.98 | $132.22 | 2024-12-04 | $121.75 | -4.3% | 48% | C |